What's New

Innophos Board of Directors Appoints Dr. Kim Ann Mink as Chairman of the Board

CRANBURY, New Jersey-(February 21, 2017)-Innophos Holdings, Inc. (NASDAQ: IPHS),
a leading international producer of performance-critical and nutritional specialty ingredients,
announced today that its Board of Directors has elected CEO and President Dr. Kim Ann Mink
to serve in the additional role of Chairman of the Board of Directors, effective today. She has
served as CEO and President since joining the Company in December 2015. Gary Cappeline,
Operating Partner of AEA Investors LLC, will continue to serve as Lead Independent Director.

"Kim Ann's strong sense of purpose, strategic leadership and business insight along with her
commitment to sound corporate governance make her immensely qualified to assume the role
of Chairman," Mr. Cappeline said. "During her tenure as CEO, she has built a top-notch
leadership team, developed a strategic roadmap for the future direction of the company, and
made excellent progress on our operational and commercial excellence initiatives. I am very
confident in Kim Ann's ability to lead the company's transformation. She is clearly the leader for
Innophos' future and has the unanimous support of the board of directors. We are excited to be
working with her."

"I am truly appreciative of the Board's vote of confidence and deeply honored by this
appointment" Dr. Mink said. "I value the opportunity to work with the Board and our talented
employees to transform Innophos into a market-oriented growth company that provides a broad
set of value-added, innovative and technology-based ingredient solutions. I am confident we will
continue to deliver value to our shareholders and customers."

About Kim Ann Mink

Kim Ann Mink, Ph.D. has been the Chief Executive Officer and President of Innophos since
December 2015 and a director of Innophos since February 2016. Prior to joining Innophos, she
served as Business President of Elastomers, Electrical and Telecommunications at The Dow
Chemical Company, or Dow Chemical, from September 2012 to December 2015. Dr. Mink
joined Dow Chemical in April 2009 as Global General Manager, Performance Materials and
President and Chief Executive Officer of ANGUS Chemical Co. (then a fully owned subsidiary of
Dow Chemical). Prior to joining Dow Chemical, Dr. Mink was Corporate Vice President and
Global General Manager, Ion Exchange Resins at the Rohm and Haas Company (now a fully
owned subsidiary of Dow Chemical), where she spent more than 20 years serving in numerous
senior roles with increasing responsibilities. From September 2012 to December 2015, Dr. Mink
served as a member of the Board of Advisors of Catalyst Inc. From November 2012 to
December 2016, she served as a member of the National Board of Trustees of the ALS
Association. In addition, in 2014, Dr. Mink was named to STEMconnector's 100 Diverse
Corporate Leaders in STEM. Dr. Mink received her B.A. in Chemistry from Hamilton College
and a Ph.D. in Analytical Chemistry from Duke University. She is a graduate of the Wharton
School of Business Management Program.

About Gary Cappeline

Gary Cappeline is currently the Lead Independent Director on the Innophos Board of Directors.
Mr. Cappeline currently serves as an Operating Partner of AEA Investors LLC, a private equity
investment fund. Before joining AEA in 2007, Mr. Cappeline was president and chief operating
officer of Ashland Inc., a diversified company, to which he returned in 2002 after service as a
senior executive in the chemical sectors at Engelhard Corporation and Honeywell International.
He also served as chemical industry partner at Bear Stearns Merchant Bank. Mr. Cappeline
currently serves on the board of directors of Evoqua Water Technologies (a manufacturer of
water purification equipment) and Swanson Industries (as chairman) (a mining equipment repair
business). He previously served as a board and executive committee member of the American
Chemistry Council (a chemical industry trade association); a director of Unifrax Corporation (a
manufacturer of high temperature insulation products); chairman and a director of Houghton
International Inc. (a manufacturer of metal working fluids); a director of Shoes for Crews, LLC (a
manufacturer of slip resistant footwear); a director of RelaDyne Inc. (a distributor of lubricants
and fuels); and a director of Tampico Beverages Inc. (a manufacturer of fruit drinks). Mr.
Cappeline earned BS and MS degrees in chemical engineering from the City College of New

About Innophos

Innophos is a leading international producer of specialty ingredient solutions that deliver farreaching,
versatile benefits for the food, health, nutrition and industrial markets. We leverage
our expertise in the science and technology of blending and formulating phosphate, mineral and
botanical based ingredients to help our customers offer products that are tasty, healthy,
nutritious and economical. Headquartered in Cranbury, New Jersey, Innophos has
manufacturing operations across the United States, in Canada, Mexico and China. For more
information, please visit www.innophos.com. 'IPHS-G'

Safe Harbor for Forward-Looking and Cautionary Statements

This release contains forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as
amended. As such, actual results could differ from estimates or expectations due to risks and
uncertainties, including but not limited to: incomplete or preliminary information; changes in
government regulations and policies; continued acceptance of Innophos' products and services
in the marketplace; competitive factors; technological changes; Innophos' dependence upon
suppliers; and other risks. For any of these factors, Innophos claims the protection of the safe
harbor for forward-looking statements contained in the Private Securities Litigation Reform Act
of 1995, as amended.

SOURCE Innophos Holdings, Inc.


Investors: Mark Feuerbach, 609-366-1204 or investor.relations@innophos.com

Media: Ryan Flaim, Sharron Merrill Associates, 617-542-5300 or IPHS@investorrelations.com